Scynexis Inc 8-K Filing

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share SCYX The Nasdaq Capital M
• $8,000,000 — to Poxel a one-time upfront payment of $8,000,000 within thirty (30) days after the effec
• $188,000,000 — acquired compound, for up to a total of $188,000,000 in aggregate milestone payments. The de
• $250,000,000 — year net sales equal to or greater than $250,000,000 $ 5,000,000 Calendar year net sales
• $500,000,000 — year net sales equal to or greater than $500,000,000 $ 25,000,000 Calendar year net sale
• $1,000,000,000 — year net sales equal to or greater than $1,000,000,000 $ 50,000,000 Calendar year net sale
• $1,500,000,000 — year net sales equal to or greater than $1,500,000,000 $ 75,000,000 Total up to: $ 188,0

Filing Documents

• d118823d8k.htm (8-K) — 42KB
• d118823dex991.htm (EX-99.1) — 18KB
• g118823g0331114854932.jpg (GRAPHIC) — 4KB
• 0001193125-26-133250.txt ( ) — 187KB
• scyx-20260330.xsd (EX-101.SCH) — 3KB
• scyx-20260330_lab.xml (EX-101.LAB) — 18KB
• scyx-20260330_pre.xml (EX-101.PRE) — 11KB
• d118823d8k_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "could," "expect," "estimate," "may," "should, "will," and "would" and similar expressions and the negatives of those terms. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this report. Examples of these forward-looking statements include, but are not limited to, statements concerning the payment(s) to be paid in connection with the Transaction, the anticipated benefits of the Transaction, the Company's ability to successfully integrate the Assets into its existing operations, the expected development timeline and regulatory pathway for the Assets, the potential commercial opportunity for products containing acquired compounds, and the Company's plans for research, development and commercialization of the AMP kinase activator program. The Company's actual results could differ materially from those anticipated in these forward-looking statements for many reasons. These risks and uncertainties include, among others: the occurrence of any event, change or other circumstances that could give rise to the termination of the Asset Purchase Agreement; the risk that the Transaction disrupts current plans and operations as a result of the announcement and consummation of the Transaction; the Company's ability to recognize the anticipated benefits of the Transaction; costs related to the Transaction, including potential milestone payment obligations; the possibility that the Company may be adversely affected by other economic, business and/or competitive factors; risks related to the protection, maintenance and enforcement of intellectual proper

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SCYNEXIS, Inc. Date: March 31, 2026 By: /s/ David Angulo, M.D. Name: David Angulo, M.D. Its: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR